Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLIDE-HCC: STRIDE plus lenvatinib versus STRIDE alone in unresectable hepatocellular carcinoma
2025-521608-23-00Phase 2Authorised
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Jun 2026
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of durvalumab, tremelimumab and lenvatinib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: Progression-free survival. Planned start Jun 2026; status: authorised.
02
Drugs
durvalumabtremelimumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2025-521608-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521608-23-00.